WASHINGTON – Two across the country known experts in hematology and sickle cell disease have became a member of Children’s National Health System in leadership roles within the Division of Hematology and the excellent Sickle Cell Disease Program. Suvankar Majumdar, M.D., may lead the hospital’s bloodstream disorders team because the Division Chief of Hematology, and Andrew Campbell, M.D., assists as Director from the Comprehensive Sickle Cell Disease Program, among the largest such programs in america. Drs. Majumdar and Campbell will build this expansive program to succeed innovations in hematology and sickle cell disease and provide exceptional choose to patients in the Washington, D.C., area and beyond.
Dr. Majumdar is really a recognized leader in hematology and sickle cell disease. Just before joining Children’s National, he offered because the Director from the Comprehensive Pediatric Sickle Cell Program in the College of Mississippi Clinic and also the Director from the Mississippi Hemophilia Treatment Facility. Additionally to his broad clinical expertise, Dr. Majumdar is definitely an accomplished investigator and Principal Investigator of National Institutes of Health-funded studies. He received his medical degree in the College of Zimbabwe College of Health Sciences and conducted his postdoctoral medical education at Michigan Condition College and also the College of Mississippi.
A noted national expert in sickle cell disease, Dr. Campbell offered as Director from the Comprehensive Sickle Cell Center in the College of Michigan for over a decade. Dr. Campbell’s research interests span several topics in sickle cell disease, including lung complications, fetal hemoglobin switching in transgenic sickle cell rodents, phenotype/genotype relationships and kidney complications. He completed school of medicine at Situation Western Reserve College and publish-graduate training at Massachusetts General Hospital (Harvard) and Lurie Children’s Hospital (Northwestern College).
“We are thrilled that Drs. Majumdar and Campbell have became a member of our distinguished group of pediatric bloodstream disorder experts,” stated Jeffrey Dome, M.D., Ph.D., V . P . from the Center for Cancer and Bloodstream Disorders at Children’s National. “From bench to bedside, Children’s National is proud to give the very indepth sickle cell and bloodstream disorders care within the Washington, D.C., area and beyond. Using the expertise and leadership of Dr. Majumdar and Dr. Campbell, we’re excited to consider pediatric hematology one stage further.Inches
The Excellent Sickle Cell Disease Program at Children’s National is probably the largest in the united states, treating greater than 1,400 children and youthful adults with lots of different sickle cell disease. Children’s National also provides the biggest, very indepth bloodstream disorders team within the Washington, D.C., area.
About Children’s National Health System
Children’s National Health System, located in Washington, D.C., continues to be serving the nation’s children since 1870. Children’s National is #1 for babies and rated in each and every niche evaluated by U.S. News & World Report including placement within the top ten for: Cancer (#7), Neurology and Neurosurgery (#9), Orthopedics (#9) and Nephrology (#10). Children’s National continues to be designated two occasions like a Magnet® hospital, a designation provided to hospitals that report the greatest standards of nursing and patient care delivery. This pediatric academic health system offers expert care via a convenient, community-based primary care network and niche outpatient centers. The place to find the Children’s Research Institute and also the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is among the nation’s top NIH-funded pediatric institutions. Children’s National is acknowledged for its expertise and innovation in pediatric care so that as a powerful voice for kids through advocacy in the local, regional and national levels. To learn more, visit ChildrensNational.org, or follow us on Facebook and Twitter.